by University of Chicago Medical Center Credit: Unsplash/CC0 Public Domain Immunotherapies have been successful in treating many cancer conditions; however, not much success has yet been achieved in metastatic castrate-resistant prostate cancer (mCRPC). A study published March 2 in Clinical Cancer Research has revealed new insights into why immunotherapies don’t tend to work as well in prostate cancer....
by Medical University of South Carolina Hollings Cancer Center researcher Nancy Klauber-DeMore, M.D., is leading the first breakthrough in pediatric osteosarcoma treatment in decades. Credit: MUSC Hollings Cancer Center/Marquel Coaxum In cancer that has not seen new targeted therapies for over 20 years, MUSC Hollings Cancer Center researcher and oncologist Nancy Klauber-DeMore, M.D., is pioneering new...
DANA-FARBER CANCER INSTITUTE Higher percentage of patients treated with nivolumab and ipilimumab in clinical trial reach the six-and-a-half-year survival mark than those treated with either drug alone. BOSTON – In the longest follow-up results from a clinical trial of combination immunotherapy for metastatic melanoma, investigators report that nearly half the patients who received the drugs nivolumab and ipilimumab were...
